Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes

Details for Australian Patent Application No. 2003248558 (hide)

Owner CV Therapeutics, Inc.

Inventors Jerling, Markus; Wolff, Andrew

Agent Freehills

Pub. Number AU-B-2003248558

PCT Number PCT/US03/16277

PCT Pub. Number WO2003/099281

Priority 60/382,781 21.05.02 US; 60/459,332 31.03.03 US

Filing date 21 May 2003

Wipo publication date 12 December 2003

Acceptance publication date 12 March 2009

International Classifications

C07D 295/14 (2006.01) Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

A61K 9/22 (2006.01) Medicinal preparations characterised by special physical form - Sustained or differential release type

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

A61K 31/496 (2006.01) - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 3/06 (2006.01) Drugs for disorders of the metabolism

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 27/02 (2006.01) Drugs for disorders of the senses

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07D 417/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

16 October 2003 Complete Application Filed

  Priority application(s): 60/382,781 21.05.02 US; 60/459,332 31.03.03 US

5 February 2004 Application Open to Public Inspection

  Published as AU-B-2003248558

12 March 2009 Application Accepted

  Published as AU-B-2003248558

9 July 2009 Standard Patent Sealed

9 July 2009 Corrigenda

  Applications Accepted - Name Index Under the name CV Therapeutics, Inc., Application No. 2003248558, under INID (54) correct the title to read Method of treating diabetes Corrigenda

15 October 2009 Amendment Made

  The nature of the amendment is: Amend the patentee name from CV Therapeutics, Inc. to Gilead Palo Alto, Inc.

2 February 2012 Assignment Registered

  Gilead Palo Alto, Inc. The patent has been assigned to Gilead Sciences Inc.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003248559-DEVICE FOR WAVELENGTH-SELECTIVE IMAGING

2003248557-SHAPE BASED NOISE CHARACTERIZATION AND ANALYSIS OF LSI